SynthesisJournal of general internal medicine2019
Pharmacotherapy for Cocaine Use Disorder-a Systematic Review and Meta-analysis.
Synthesis in Journal of general internal medicine, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03192995 (Treatment With Lorcaserin for Cocaine Use), which is not on this map. Cited by 71 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Treatment With Lorcaserin for Cocaine Use: The TLC Study
Who cites it
71 citing papers in PubMed, 9 syntheses or guidelines pooled it, 138 citations in OpenAlex.
- Diagnostic challenges in infant death associated with maternal cocaine abuse during pregnancy and lactation: a forensic case report and review of the literature.Frontiers in pediatrics · 2026Pooled it
- Psychosocial interventions for stimulant use disorder.The Cochrane database of systematic reviews · 2024Pooled it
- Disulfiram for the treatment of cocaine dependence.The Cochrane database of systematic reviews · 2024Pooled it
- Running with Scissors: a Systematic Review of Substance Use and the Pre-exposure Prophylaxis Care Continuum Among Sexual Minority Men.Current HIV/AIDS reports · 2022Pooled it
- Pooled it
- A systematic review and meta-analysis of medications for stimulant use disorders in patients with co-occurring opioid use disorders.Drug and alcohol dependence · 2020Pooled it
- Prescription psychostimulants for the treatment of stimulant use disorder: a systematic review and meta-analysis.Psychopharmacology · 2020Pooled it
- Pooled it
- The ASAM/AAAP Clinical Practice Guideline on the Management of Stimulant Use Disorder.Journal of addiction medicineGuideline
- Psilocybin in the Treatment of Cocaine Use Disorder: A Randomized Clinical Trial.JAMA network open · 2026Trial
- The synergy of methylphenidate- and reconsolidation-based extinction normalizes ventromedial prefrontal function in drug addiction.Proceedings of the National Academy of Sciences of the United States of America · 2025Trial
- The role of Iowa gambling task performance in response to citalopram treatment for cocaine use disorder.The American journal of drug and alcohol abuse · 2025Trial
- Barriers and facilitators to medication-assisted treatment for cocaine use disorder among men who have sex with men: a qualitative study.Addiction science & clinical practice · 2024Trial
- Exploring cannabidiol effects on inflammatory markers in individuals with cocaine use disorder: a randomized controlled trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2021Trial
- Citalopram for treatment of cocaine use disorder: A Bayesian drop-the-loser randomized clinical trial.Drug and alcohol dependence · 2021Trial
- Cannabidiol as a treatment for craving and relapse in individuals with cocaine use disorder: a randomized placebo-controlled trial.Addiction (Abingdon, England) · 2021Trial
- Trial
- Repeated measures latent class analysis identifies unique daily cocaine-use patterns and associated clinical characteristics: A timeline followback-based analytic approach.Drug and alcohol dependence reports · 2026Article
- Glucagon-Like Peptide-1 Receptor Agonists in Cocaine Use Disorder: Clinical Observations and Underlying Mechanisms.Fundamental & clinical pharmacology · 2026Review
- Factors Associated With Cocaine Use Disorder: Results From the French Nationwide Repeated Cross-Sectional OPPIDUM Study (2019-2023).Fundamental & clinical pharmacology · 2026Article
11 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundCurrently, there are no accepted FDA-approved pharmacotherapies for cocaine use disorder, though numerous medications have been tested in clinical trials. We conducted a systematic review and meta-analysis to better understand the effectiveness of pharmacotherapy for cocaine use disorder.
methodsWe searched multiple data sources (MEDLINE, PsycINFO, and Cochrane Library) through November 2017 for systematic reviews and randomized controlled trials (RCTs) of pharmacological interventions in adults with cocaine use disorder. When possible, we combined the findings of trials with comparable interventions and outcome measures in random-effects meta-analyses. We assessed the risk of bias of individual trials and the strength of evidence for each outcome using standardized criteria. Outcomes included continuous abstinence (3+ consecutive weeks); cocaine use; harms; and study retention. For relapse prevention studies (participants abstinent at baseline), we examined lapse (first cocaine positive or missing UDS) and relapse (two consecutive cocaine positive or missed UDS').
resultsSixty-six different drugs or drug combinations were studied in seven systematic reviews and 48 RCTs that met inclusion criteria. Antidepressants were the most widely studied drug class (38 RCTs) but appear to have no effect on cocaine use or treatment retention. Increased abstinence was found with bupropion (2 RCTs: RR 1.63, 95% CI 1.02 to 2.59), topiramate (2 RCTs: RR 2.56, 95% CI 1.39 to 4.73), and psychostimulants (14 RCTs: RR 1.36, 95% CI 1.05 to 1.77), though the strength of evidence for these findings was low. We found moderate strength of evidence that antipsychotics improved treatment retention (8 RCTs: RR 1.33, 95% CI 1.03 to 1.75). DISCUSSION: Most of the pharmacotherapies studied were not effective for treating cocaine use disorder. Bupropion, psychostimulants, and topiramate may improve abstinence, and antipsychotics may improve retention. Contingency management and behavioral interventions along with pharmacotherapy should continue to be explored. SR REGISTRATION: Prospero CRD42018085667.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.